Total Voting Rights

Report this content

3 January 2017 16:00

Transparency Directive 

Voting Rights and Capital 

The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. On 31 December 2016 the issued share capital of AstraZeneca PLC with voting rights is 1,265,229,424 ordinary shares of US$0.25.  No shares are held in Treasury.  Therefore, the total number of voting rights in AstraZeneca PLC is 1,265,229,424. 

The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules. 

  

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

Media Enquiries           
Neil Burrows    UK/Global    +44 203 749 5637   
Vanessa Rhodes    UK/Global    +44 203 749 5736   
Karen Birmingham    UK/Global    +44 203 749 5634   
Rob Skelding    UK/Global    +44 203 749 5821   
Jacob Lund    Sweden    +46 8 553 260 20   
Michele Meixell    US    +1 302 885 2677   
Investor Relations
Thomas   Kudsk Larsen   +44 203 749 5712 
Craig   Marks  Finance, Fixed Income, M&A +44 7881 615 764 
Henry   Wheeler  Oncology +44 203 749 5797 
Mitchell   Chan  Oncology +1 240 477 3771 
Lindsey   Trickett  Cardiovascular & Metabolic   Diseases +1 240 543 7970 
Nick   Stone  Respiratory +44 203 749 5716 
Christer   Gruvris Autoimmunity, neuroscience &   infection +44 203 749 5711
US toll free +1 866 381 7277

Adrian Kemp

Company Secretary, AstraZeneca PLC

-ENDS-

Subscribe

Documents & Links